Symptoms and General Pathology

All Conditions

Neoplasms

Blood and Lymph Conditions

Immune System Diseases

Infections

Skin and Connective Tissue Diseases

Rare Diseases

Syndrome

Lymphoma

Mycoses

Mycosis Fungoides

Skin Neoplasms

Sezary Syndrome

Communicable Diseases

Bacterial Infections

Bacterial Infections and Mycoses

Lymphoma, T-Cell

Lymphoma, T-Cell, Cutaneous

Lymphoma, Non-Hodgkin

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphosarcoma

The study aims to perform systematic translational sampling of each patient from study start until end-of-study, or at longest for a three year period for each patient. Treatment will be performed according to clinical routine.

Blood tests and testing of analysis of the lymphoma microenvironment in skin, skin barrier and skin microbiology profile.

Kristina Drott, MD, PhD

Jan Sundberg, RN

A translational study for identification of prognostic and treatment-predictive biomarkers in Mycosis fungoides and Sézary syndrome.

• Lymphocyte subpopulations:

* Basic examination lymphocytes: CD3, CD4, CD8, CD19, CD16/56
* T regs: CD4, CD25, CD194, CD127, CD45RO, HLA-DR
* Naive and memory T-cells including TH1, TH2, TH17: CD4, CD8, CD197, CD45RA, CD183, CD196
* Follicular helper T cells: CD4, CD185
* T-cells : CD4, CD8, CD197, CD45RA, CD38, HLA-DR
* Other leukocytes, at the discretion of the treating physician
* sILR2R, IL6, IL1 beta, IL-8, IL10, TARC

Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome.

Skin barrier analyzed by transepidermal water loss of the skin on both healthy and affected skin.

Lund University Hospital

Carcinoma

Melanoma

Carcinoma, Squamous Cell

Carcinoma, Basal Cell

Neoplasms, Glandular and Epithelial

Skin Diseases

Neoplasms, Basal Cell

patients with a skin lymphoma OR melanoma OR advanced skin squamous cell carcinoma OR advanced basal cell carcinoma accepting to answer to the anonymous survey

we will ask patients to answer to a survey

no intervention, only complete a survey

Anne-Claire BURSZTEJN

anne-claire Bursztejn

anne-claire bursztejn

The law about advance directives is evolving but, in France, few people write it.

Te main endpoint of this research is to estimate the proportion of patients who have written their advance directives or considering doing so in onco-dermatologic population. If this rate remains low, some insights on the reasons will be able to be advanced looking at the point of view and opinion of patients about this topic.

Seconds endpoints are :

For patients against or not planning to write it, understand their reasons

Estimate the proportion of patients requesting information and understand how they would like to receive it.

Investigate a possible association between the stage of the oncological disease and the positioning of the patient concerning advance directives.

ACCEPTABILITY AND WRITING FREQUENCY OF ADVANCED DIRECTIVES IN ONCO-DERMATOLOGY PATIENTS

Writing by the patient of his advance directves and, if not writing, positioning of the patient (rather favorable or rather unfavorable) as to the writing of his advance directives.

In patients who have not written their advance directives: reason for not writing the advance directives.

Central Hospital, Nancy, France

Lymphoma, T-Cell, Peripheral

Hematologic Diseases

Lymphomatoid Papulosis

Lymphoma, Primary Cutaneous Anaplastic Large Cell

Peripheral T-cell Lymphoma

Cutaneous T-cell Lymphoma

Antineoplastic Agents

All Drugs and Chemicals

Brentuximab Vedotin

Antineoplastic Agents, Immunological

Immunotoxins

Immunoconjugates

Immunologic Factors

1.8 mg/kg intravenously Day 1 of 21-day cycle.

1.8 mg/kg administered by outpatient IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle.

SGN-35

Ronald P. Rapini, MD

The goal of this clinical research study is to learn if SGN-35 (brentuximab vedotin) can help to control ALCL, LyP or MF in patients with at least 1 of the 3 skin lymphomas. The safety of the study drug will also be studied.

The Study Drug:

Brentuximab vedotin is an antibody that is designed to find a certain protein (called CD30) on cancer cells and bind to it. It is designed to then enter the cell and release a molecule that may kill the cancer cells.

Study Drug Administration:

If you are found eligible to take part in this study, you will begin receiving brentuximab vedotin by vein over 30 minutes on Day 1 of each 21-day study cycle. If you have side effects after your first dose and your doctor thinks it is in your best interest, future doses may be lowered or delayed for up to 3 weeks.

Premedications:

If you have any reactions at the infusion site after you receive the study drug during Cycle 1, you may be given acetaminophen (Tylenol) or diphenhydramine (Benadryl) 30-60 minutes before all following infusions.

Study Visits:

At each clinic visit, including follow-up visits (described below), you will have full skin exams. You will be checked to see how much of your skin's surface has lesions. Up to 6 skin lesions will be selected to be photographed and measured at each visit. Your private areas will be covered (as much as possible), and a picture of your face will not be taken unless there are lesions on your face. You will not be able to be identified in the photographs. The following tests and procedures will also be performed:

On Day 1 of all study cycles (before you receive the study drug):

* You will have a physical exam.
* Your performance status will be recorded.
* You will be asked about any drugs that you may be taking and if you are having any side effects.
* You will complete 5 questionnaires about your quality of life and itching symptoms.
* Blood (about 4-6 teaspoons) will be drawn for routine tests and to check the status of the disease.
* If you have not had a lesion biopsy within the last 6 weeks you will have a lesion biopsy to check the status of the disease and for PGx testing.

Length of Study Treatment:

You may receive the study drug for up to 8 cycles. You will be taken off study if the disease gets worse or intolerable side effects occur.

If the disease has a complete response, you may receive the study drug for 2 more cycles if the study doctor thinks it is in your best interest.

If the disease has complete response, then comes back, you may receive the study drug for 8 more cycles if the doctor thinks it is in your best interest.

If you are doing better at the end of 8 cycles but the disease is not in complete remission, the study doctor may allow you to receive the study drug every 3 weeks at the full dose or every 2 weeks at a lower dose for 8 additional cycles. If you continue to have improvement after these 16 cycles, the study doctor may allow you to continue receiving the study drug. The study doctor will discuss this with you.

Follow-up Visits:

About 3-4 weeks after you have stopped taking the study drug, the following tests and procedures will be performed:

* Your medical history will be recorded.
* Your performance status will be recorded.
* You will have a physical exam.
* You will be asked if you are having any side effects.
* You will complete 5 questionnaires about your quality of life and itching symptoms.
* Blood (about 4-6 teaspoons) will be drawn for routine tests and to check the status of the disease.
* You will have a CT or PET scan to check the status of the disease.
* You will have a lesion biopsy to check the status of the disease and for PGx testing.

Long-term Follow-up:

You or your primary doctor may be contacted for long-term follow-up on the status of the disease, any study-related nerve damage (including loss of motor or sensory function) you have, and your overall health status.

Follow-up will be every 12-16 weeks for the first 2 years after the last dose. Then, the follow-up will be every 6 months (+/- 1 month) up to a maximum period of 5 years.

This is an investigational study. Brentuximab vedotin is FDA approved and commercially available for use in patients with ALCL. It is currently being used for LyP and MF for research purposes only. You will receive $15 coupons for valet parking for each clinic visit you make during this study.

Up to 84 patients will take part in this study. All will be enrolled at MD Anderson.

SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)

Phase II Trial of Brentuximab Vedotin (SGN-35) at Dose of 1.8 mg/kg IV Every 3 Weeks in Patients With CD30-positive Lymphoproliferative Disorders (Cutaneous Anaplastic Large T-cell Lymphoma (ALCL), Mycosis Fungoides, and Extensive Lymphomatoid Papulosis (LyP)

Response rate is percentage of participants with skin lesions that express CD30+ receiving SGN-35 in primary cutaneous ALCL, MF, and extensive lymphomatoid papulosis whose best response during the observation period is a Partial Response (PR), regression of measurable disease, or Complete Response (CR), complete disappearance of all clinical evidence of disease, (i.e. at least moderate improvement). Objective tumor response (PR, CR, PR+CR) based on Response Evaluation Criteria In Solid Tumors (RECIST) criteria.

Time to progression calculated as the time (days) from date of first dose of study drug to date of first observed progression or death date if the death was due to disease progression whichever comes first.

Seagen Inc.

M.D. Anderson Cancer Center

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome.	NCT04904146	Mycosis Fungoid... Sezary Syndrome	Blood tests and...	18 Years - 100 Years	Lund University Hospital
ACCEPTABILITY AND WRITING FREQUENCY OF ADVANCED DIRECTIVES IN ONCO-DERMATOLOGY PATIENTS	NCT03822988	Advance Directi... Oncology Skin Cancer Melanoma Skin Lymphoma Skin Squamous C... Metastatic Basa...	no intervention...	18 Years -	Central Hospital, Nancy, France
SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)	NCT01352520	CD-30 Positive ... Lymphoma, Prima... Lymphomatoid Pa... Mycosis Fungoid... Skin Lymphoma Cutaneous Lymph... Lymphoma Hematologic Dis...	SGN-35	18 Years -	M.D. Anderson Cancer Center

Spots Global Cancer Trial Database for skin lymphoma